The role of prostate-specific antigen in the osteoblastic bone metastasis of prostate cancer: a literature review

Prostate cancer is the only human malignancy that generates predominantly osteoblastic bone metastases, and osteoblastic bone metastases account for more than 90% of osseous metastases of prostate cancer. Prostate-specific antigen (PSA) plays an important role in the osteoblastic bone metastasis of prostate cancer, which can promote osteomimicry of prostate cancer cells, suppress osteoclast differentiation, and facilitate osteoblast proliferation and activation at metastatic sites. In the meantime, it can activate osteogenic factors, including insulin-like growth factor, transforming growth factor beta 2 and urokinase-type plasminogen activator, and meanwhile suppress osteolytic factors such as parathyroid hormone-related protein. To recapitulate, PSA plays a significant role in the osteoblastic predominance of prostate cancer bone metastasis and bone remodeling by regulating multiple cells and factors involved in osseous metastasis.

Automated summary

Prostate cancer is unique in its ability to predominantly generate osteoblastic bone metastases, which account for over 90% of prostate cancer bone metastases. Prostate-specific antigen (PSA) plays a crucial role in this process by promoting osteomimicry of cancer cells, inhibiting osteoclast differentiation, and facilitating osteoblast proliferation and activation at metastatic sites. Furthermore, PSA activates osteogenic factors while suppressing osteolytic factors, contributing to the predominance of osteoblastic bone metastasis and bone remodeling in prostate cancer.